SHENZHEN, China, July 12, 2024 /PRNewswire/ — The 2nd Ambulatory Glucose Profile (AGP) & Digital Therapeutics (DTx) Summit, organized by the National Innovation Center for Advanced Medical Devices and sponsored by the China AGP and DTx Digital Therapeutics R&D Center, was successfully held in Shenzhen, China on July 5th. Co-sponsored by Shenzhen SIBIONICS Technology Co., Ltd., the event brought together healthcare experts from around the world to delve into the precision diagnosis and treatment of diabetes through AGP and the role of digital therapeutics in clinical decision-making.
Led by Professor Ji Linong, founder of the China AGP&DTx R&D Center and clinical professor at Peking University People’s Hospital, the summit featured renowned endocrinologists from Slovenia, Australia, Saudi Arabia, Serbia, Turkey, and Algeria. Key discussions included AGP consensus, the utilization of the Chinese diabetes patient database, advancements in the artificial pancreas system, and innovations in digital health management. These topics underscored the latest breakthroughs in diabetes technology and their practical implications in clinical settings.
During the conference, Professor Andrej Janež from Ljubljana University Medical Centre praised China’s progress in AGP clinical practices, noting the development of training programs and the integration of AI for enhanced diagnosis and treatment guidance. These advancements promise to elevate diabetes care globally and foster broader AGP applications.
An important outcome of the summit was the establishment of the International Consortium for AGP&DTx R&D, aimed at standardizing AGP clinical applications worldwide. This consortium seeks to facilitate international collaboration and knowledge exchange to advance diabetes diagnosis and treatment on a global scale.
About SIBIONICS
Founded in 2015, SIBIONICS specializes in the research and development of implantable medical devices. Focused on integrating state-of-the-art CGM technology with patient-centric designs, SIBIONICS pioneers personalized solutions for diabetes management. With a user base exceeding 1,000,000 globally, SIBIONICS continues to lead in reliability and innovation within the diabetes management sector.
Related topics:
Gestational Diabetes: Latest Research Updates
Combination of Semaglutide and Very-Low Calorie Diet Shows Superior Diabetes Management
Enhanced Diabetes Drug Combo Offers Heart and Kidney Protection
